Insider Buying Signals Confidence in Nektar’s Oncology Pipeline Amid Market Volatility
Insider buying by Whitfield Roy A. signals cautious optimism for Nektar Therapeutics, but a falling share price, negative earnings, and macro‑headwinds urge investors to watch upcoming clinical milestones closely.
4 minutes to read